Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patientsJANELSINS, Michelle C; TEJANI, Mohamedtaki A; KAMEN, Charles et al.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 6, pp 757-766, issn 1465-6566, 10 p.Article

Clonazepam for Chemotherapy-induced Nausea and Vomiting (CINV)KOGA, Minako; NAKADOZONO, Momoe; NUKARIYA, Kazutaka et al.Anticancer research. 2008, Vol 28, Num 4C, pp 2433-2436, issn 0250-7005, 4 p.Article

Genetic factors associated with pharmacotherapy and background sensitivity to postoperative and chemotherapy-induced nausea and vomitingJANICKI, Piotr K; SUGINO, Shigekazu.Experimental brain research. 2014, Vol 232, Num 8, pp 2613-2625, issn 0014-4819, 13 p.Conference Paper

Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapySHIH, Ya-Chen Tina; YING XU; ELTING, Linda S et al.Cancer. 2007, Vol 110, Num 3, pp 678-685, issn 0008-543X, 8 p.Article

Pharmacokinetics, metabolism and excretion of intravenous [¹⁴C]-palonosetron in healthy human volunteersSTOLTZ, Randall; PARISI, Simona; SHAH, Ajit et al.Biopharmaceutics & drug disposition. 2004, Vol 25, Num 8, pp 329-337, issn 0142-2782, 9 p.Article

Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescentsSMITH, Angela R; REPKA, Tanya L; WEIGEL, Brenda J et al.Pediatric blood & cancer. 2005, Vol 45, Num 6, pp 857-860, issn 1545-5009, 4 p.Article

Clinical practice guidelines on antiemetics in oncologyAGUILAR, Enrique Aranda; FIGUEIRAS, Manuel Constenla; CORTES-FUNES, Hernan et al.Expert review of anticancer therapy. 2005, Vol 5, Num 6, pp 963-972, issn 1473-7140, 10 p.Article

The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centersIHBE-HEFFINGER, A; EHLKEN, B; BERNARD, R et al.Annals of oncology. 2004, Vol 15, Num 3, pp 526-536, issn 0923-7534, 11 p.Article

Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCTMUSSO, M; SCALONE, R; CRESCIMANNO, A et al.Bone marrow transplantation (Basingstoke). 2010, Vol 45, Num 1, pp 123-127, issn 0268-3369, 5 p.Article

A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapySEGAWA, Y; AOGI, K; INOUE, K et al.Annals of oncology. 2009, Vol 20, Num 11, pp 1874-1880, issn 0923-7534, 7 p.Article

Is there a pharmacological basis for differences in 5-HT₃-receptor antagonist efficacy in refractory patients?DE WIT, Ronald; AAPRO, Matti; BLOWER, Peter R et al.Cancer chemotherapy and pharmacology. 2005, Vol 56, Num 3, pp 231-238, issn 0344-5704, 8 p.Article

Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomitingNAKADE, Susumu; OHNO, Tomoya; KITAGAWA, Junsaku et al.Cancer chemotherapy and pharmacology. 2008, Vol 63, Num 1, pp 75-83, issn 0344-5704, 9 p.Article

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapyAAPRO, M. S; GRUNBERG, S. M; MACCIOCCHI, A et al.Annals of oncology. 2006, Vol 17, Num 9, pp 1441-1449, issn 0923-7534, 9 p.Article

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled StudyMIZUKAMI, Naomi; YAMAUCHI, Masanori; KOIKE, Kazuhiko et al.Journal of pain and symptom management. 2014, Vol 47, Num 3, pp 542-550, issn 0885-3924, 9 p.Article

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT₃ receptor antagonist: Results of a phase III, single-dose trial versus dolasetronEISENBERG, Peter; FIGUEROA-VADILLO, Jazmin; ZAMORA, Rosalio et al.Cancer. 2003, Vol 98, Num 11, pp 2473-2482, issn 0008-543X, 10 p.Article

Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor typesAAPRO, Matti S; SCHMOLL, Hans J; JAHN, Franziska et al.Cancer treatment reviews. 2013, Vol 39, Num 1, pp 113-117, issn 0305-7372, 5 p.Article

Netupitant and palonosetron trigger NK₁ receptor internalization in NG108-15 cellsTHOMAS, Ajit G; STATHIS, Marigo; ROJAS, Camilo et al.Experimental brain research. 2014, Vol 232, Num 8, pp 2637-2644, issn 0014-4819, 8 p.Conference Paper

Comparative activity of antiemetic drugsJORDAN, Karin; SCHMOLL, Hans J; AAPRO, Matti S et al.Critical reviews in oncology/hematology. 2007, Vol 61, Num 2, pp 162-175, issn 1040-8428, 14 p.Article

Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index: Emesis (FLIE) with 5-day recallMARTIN, A. R; PEARSON, J. D; CAI, B et al.Supportive care in cancer. 2003, Vol 11, Num 8, pp 522-527, issn 0941-4355, 6 p.Article

Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trialSAITO, H; YOSHIZAWA, H; YOSHIMORI, K et al.Annals of oncology. 2013, Vol 24, Num 4, pp 1067-1073, issn 0923-7534, 7 p.Article

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetronGRALLA, R; LICHINITSER, M; VAN DER VEGT, S et al.Annals of oncology. 2003, Vol 14, Num 10, pp 1570-1577, issn 0923-7534, 8 p.Article

Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen failsWEIHENG HU; JIAN FANG; JUN NIE et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 6, pp 1129-1136, issn 0344-5704, 8 p.Article

The role of second-generation 5-HT₃ receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignanciesSCHWARTZBERG, Lee S; JACOBS, Peter; MATSOUKA, Panagiota et al.Critical reviews in oncology/hematology. 2012, Vol 83, Num 1, pp 59-70, issn 1040-8428, 12 p.Article

Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in GermanyLORDICK, Florian; EHLKEN, Birgit; IHBE-HEFFINGER, Angela et al.European journal of cancer (1990). 2007, Vol 43, Num 2, pp 299-307, issn 0959-8049, 9 p.Article

5-HT₃-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatmentAAPRO, Matti.Oncology. 2005, Vol 69, Num 2, pp 97-109, issn 0030-2414, 13 p.Article